C12orf48, Termed PARP-1 Binding Protein, Enhances Poly(ADP-Ribose) Polymerase-1 (PARP-1) Activity and Protects Pancreatic Cancer Cells from DNA Damage

Lianhua Piao,[1] Hidewaki Nakagawa,[1,2] Koji Ueda,[2] Suyoun Chung,[1] Kotoe Kashiwaya,[1] Hidetoshi Eguchi,[3] Hiroaki Ohigashi,[3] Osamu Ishikawa,[3] Yataro Daigo,[1] Koichi Matsuda,[1] and Yusuke Nakamura[1]*

[1]Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
[2]Laboratory for Biomarker Development, Center of Genomic Medicine, RIKEN, Yokohama, Japan
[3]Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan

To identify novel therapeutic targets for aggressive and therapy-resistant pancreatic cancer, we had previously performed expression profile analysis of pancreatic cancers using microarrays and found dozens of genes trans-activated in pancreatic ductal adenocarcinoma (PDAC) cells. Among them, this study focused on the characterization of a novel gene *C12orf48* whose overexpression in PDAC cells was validated by Northern blot and immunohistochemical analysis. Its overexpression was observed in other aggressive and therapy-resistant malignancies as well. Knockdown of C12orf48 by siRNA in PDAC cells significantly suppressed their growth. Importantly, we demonstrated that C12orf48 protein could directly interact with Poly(ADP-ribose) Polymerase-1 (PARP-1), one of the essential proteins in the repair of DNA damage, and positively regulate the poly(ADP-ribosyl)ation activity of PARP-1. Depletion of C12orf48 sensitized PDAC cells to agents causing DNA damage and also enhanced DNA damage-induced G2/M arrest through reduction of PARP-1 enzymatic activities. Hence, our findings implicate C12orf48, termed PARP-1 binding protein (PARPBP), or its interaction with PARP-1 to be a potential molecular target for development of selective therapy for pancreatic cancer.

INTRODUCTION

Pancreatic cancer is the fourth leading cause of cancer death in the western world and shows the worst mortality among common malignancies with a 5-year survival rate of lower than 5% (DiMagno et al., 1999; Wray et al., 2005). It is estimated that a total of 42,470 new cases were diagnosed to have pancreatic cancer and 35,240 deaths were caused by it in the United States in 2009 (Jemal et al., 2009). At present, only surgical resection can offer a chance for cure or long-term survival to the patients suffering from pancreatic cancer. However, only 10–20% of patients with pancreatic cancer are able to have radical surgery because most of the patients are already at an advanced stage at the time of diagnosis (DiMagno et al., 1999; Wray et al., 2005). Gemcitabine or 5-fluorouracil chemotherapy coupled with radiotherapy could improve the quality of life of the patients (DiMagno et al., 1999; Wray et al., 2005), but its survival benefit is very limited. Hence, there has been no substantial improvement in relative 5-year survival rate for pancreatic cancer in the past 3 decades (Jemal et al., 2009). To overcome this dismal situation, development of novel molecular therapies targeting a molecule specifically functioning in pancreatic cancer is eagerly awaited. We had previously performed extensive genome-wide expression profile analysis of pancreatic cancer cells in combination with microdissection to enrich cancer cell population (Nakamura et al., 2004), and demonstrated some genes trans-activated in PDAC cells to be possible molecular targets for development of new therapeutic modalities to treat pancreatic cancers (Taniuchi et al., 2005a,b; Iiizumi et al., 2006; Takehara et al., 2006, 2007; Hosokawa et al., 2007, 2008; Kashiwaya et al., 2009).

Poly(ADP-ribose) polymerase-1 (PARP-1), a nuclear enzyme, catalyzes the transfer of the ADP-ribose unit from its substrate, NAD^+, to some protein acceptors such as histones, p53, and PARP-1 itself. The addition of negatively charged polymers profoundly alters the properties

Additional Supporting Information may be found in the online version of this article.

Supported by: Japan Society for the Promotion of Science, Grant number: 00L01402.

*Correspondence to: Yusuke Nakamura, M.D., Ph.D., Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan. E-mail: yusuke@ims.u-tokyo.ac.jp

Received 28 July 2010; Accepted 2 September 2010

DOI 10.1002/gcc.20828

Published online 7 October 2010 in Wiley Online Library (wileyonlinelibrary.com).

and functions of the target proteins. Through its physical association with partner proteins or by the poly(ADP-ribosyl)ation of them, PARP-1 is involved in multiple cellular processes including DNA repair, transcriptional regulation, chromatin modification, cell cycle progression, or genomic stability (Ogata et al., 1981; Kameshita et al., 1984). PARP-1 is a molecular nick-sensor of DNA breaks and has a critical role in the spatial and temporal organization of the DNA repairs (de Murcia et al., 1994). The activation of PARP-1 after DNA damage provides rapid signals to halt transcription and recruits enzymes required for DNA repair to the site of DNA damage, including XRCC1, DNA ligase III, and DNA polymerase β. PARP-1 is essential in the repair of both DNA single-strand breaks (SSB) as well as double-strand breaks (DSB) (Durkacz et al., 1980; D'Silva et al., 1999; Dantzer et al., 2000; Audebert et al., 2004, 2006; Wang et al., 2006). The involvement of PARP-1 in the DNA repair system prompted us to investigate the effect of PARP-1 inhibition on DNA-damaging anticancer therapies (Daniel et al., 2009; Horton et al., 2009). Inhibition of PARP-1 enhanced the cytotoxicity of DNA-damaging agents and seemed to overcome one of the causes of resistance in cancer cells to anticancer treatment (Hoeijmakers et al., 2001; Longley and Johnston, 2005). Currently, several PARP-1 inhibitors have already been taken into the clinical trials as chemopotentiating or radio-potentiating agents, and have shown promising results (Miknyoczki et al., 2007; Plummer et al., 2008; Rottenberg et al., 2008; Horton et al., 2009; Jones et al., 2009; O'Shaughnessy et al., 2009).

We here focus on the characterization of a novel gene *C12orf48* (*Chromosome 12 open reading frame 48*). We demonstrate that C12orf48 protein can interact with PARP-1 directly and be involved in the repair of DNA breaks through enhancing PARP-1 activity. Thus, we termed this molecule PARP-1 binding protein (PARPBP). These findings indicate that C12orf48, or its interaction with PARP-1 could be a promising molecular target for the development of novel treatment for pancreatic cancer.

MATERIALS AND METHODS

Cell Lines

PDAC cell lines, KLM-1, SUIT-2, KP-1N, PK-1, PK-45P, and PK-59, were provided from Cell Resource Center for Biomedical Research, Tohoku University (Sendai, Japan). MIAPaCa-2, Panc-1 and COS7 cell lines were purchased from the American Type Culture Collection (ATCC, Rockville, Maryland). KLM-1, SUIT-2, PK-1, PK-45P, PK-59 and Panc-1, were grown in RPMI 1640 (Sigma-Aldrich, St. Louis, Missouri), and COS7, MIAPaCa-2 in DMEM (Sigma-Aldrich), with 10% fetal bovine serum and 1% antibiotic/antimycotic solution (Sigma-Aldrich).

Semi-Quantitative Reverse Transcription-PCR

Microdissection of PDAC cells and normal pancreatic ductal cells were described previously (Nakamura et al., 2004). RNAs from these cells were subjected to two rounds of RNA amplification using T7-based in vitro transcription (Epicenter Technologies, Madison, Wisconsin). Total RNAs from human PDAC cell lines were extracted using Trizol reagent (Invitrogen) according to the manufacturer's instructions. Extracted RNAs were treated with DNase I (Roche, Mannheim, Germany) and reversely transcribed to single-stranded cDNAs using oligo $(dT)_{12–18}$ primer with Superscript II reverse transcriptase (Invitrogen). The primer sequences were 5′-TTGGCTTGACTCAGGATTTA-3′ and reverse 5′-ATGCTATCACCTCCCCTGTG-3′ for β-*actin* (*ACTB*), and 5′-CTCAGCTGGG AAAGCTACAGAT-3′ and 5′-CATGCCAGGT AGTTCTTCCATC-3′ for *C12orf48* (GenBank Accession no. NM_017915). Each PCR regime involved initial denaturation at 94°C for 2 min followed by 23 cycles (for *ACTB*), 28 cycles (for *C12orf48*) at 94°C for 30 sec, 55°C for 30 sec, and 72°C for 1 min.

Northern Blot Analysis

One μg each of polyA RNA extracted from eight PDAC cell lines (KLM-1, PK-59, PK-45P, MIAPaCa-2, KP-1N, Panc-1, PK-1, and SUIT-2) and seven adult normal tissues (heart, lung, liver, kidney, brain, testis, and pancreas, from BD Bioscience, Palo Alto, CA) was blotted onto a nylon membrane. The 305-bp probe specific to *C12orf48* was prepared by PCR using the primer set described above. The cancer membrane and human Multiple Tissue Northern blot membrane (Clontech, Mountain View, CA) were hybridized with the cDNA probe labeled with α^{32}P-dCTP using Mega Label kit (GE Healthcare, Piscataway, New Jersey). Prehybridization, hybridization, and

washing were performed according to the manufacturer's instruction. The blots were autoradiographed at −80°C for 10 days.

Generation of Antibodies to C12orf48 and Immunocytochemistry/Immunohistochemistry

Plasmids expressing two fragments of C12orf48 (codons 1–150 and 328–498) in pET21a(+) vector (Novagen, Madison, Wisconsin) were constructed to produce recombinant proteins in *E. coli*. The recombinant C12orf48 proteins were purified using Ni-NTA resin agarose (Qiagen, Valencia, CA) and used to immunize rabbits. The sera from the immunized rabbits were purified by antigen-Affi-Gel 10 (Bio-Rad Laboratories, Hercules, CA) affinity column chromatography. For immunocytochemical analysis, KLM-1 cells fixed by 4% paraformaldehyde were incubated with rabbit anti-C12orf48 polyclonal antibody for 1 hr. After washing with PBS, the cells were stained by Alexa 488-conjugated anti-rabbit IgG secondary antibodies (Molecular Probes, Eugene, Oregon) for 1 hr. Stained preparations were mounted with VECTASHIELD mounting medium with DAPI (Vector Laboratories, Burlingame, CA). For immunohistochemistry, tissue sections of PDACs were obtained from the Osaka Medical Center for Cancer and Cardiovascular Diseases under the written informed consent. Human PDAC tissue microarrays were purchased from ISU-ABXIS (Accurate Chemical Corp., Westbury, New York). The sections were deparaffinized and autoclaved at 108°C in Dako Cytomation Target Retrieval Solution High pH (Dako Cytomation, Carpinteria, CA) for 15 min. After blocking, the sections were incubated with rabbit anti-C12orf48 antibody (dilution 1:2,500) at room temperature for 1 hr, washed three times in PBS, and incubated with peroxidase labeled anti-rabbit immunoglobulin (Envision kit; Dako Cytomation). Finally, the reactants were developed with 3,3′-diaminobenzidine. Counterstaining was performed using hematoxylin.

Short-Hairpin RNA-Expressing Constructs

The psiU6BX3.0 vector for expression of short-hairpin RNA (shRNA) was constructed to knock down the expression of the target genes, as described previously (Taniuchi et al., 2005b). The target sequences for *C12orf48* were 5′-CACAGTATCTCCTAGTCAA-3′ (si1), 5′-GTTGCTCAGGATTTGGATT-3′ (si2), 5′-GCAGCTAATGCTCCTACCA-3′ (si3), and 5′-GAAGCAGCACGACTTCTTC-3′ (siEGFP) as a negative control. PDAC cell lines, KLM-1 and SUIT-2, were transfected with each of these shRNA-expression vectors using FuGENE6 (Roche), and selected with Geneticin (GIBCO, 0.5 mg/mL for KLM-1 cells and 0.9 mg/mL for SUIT-2 cells, respectively). Cell viability was measured using cell-counting kit-8 (DOJINDO, Kumamoto, Japan) 6 days after the transfection. Absorbance was measured at 490 nm, and at 630 nm as reference, with a Microplate Reader 550 (Bio-Rad). After 2 weeks of the selection, cancer cells were fixed with 100% methanol and stained with 0.1% of crystal violet-H_2O.

Immunoprecipitation and Mass-Spectrometric Analysis

The pCAGGS Flag-C12orf48-HA vector was constructed by PCR cloning, and was transfected to HEK293 cells. The transfected cells were lysed in lysis buffer (50 mmol/L Tris-HCl [pH 8.0], 0.4% NP-40, 150 mmol/L NaCl, Protease Inhibitor Cocktail Set III [Calbiochem, San Diego, CA]). Cell extracts were precleared by incubation with CL-4B sepharose (Sigma-Aldrich) at 4°C for 1 hr, and incubated with anti-FLAG M_2-agarose (Sigma-Aldrich) for 1 hr. The proteins were separated in 5–20% gradient SDS-PAGE gels (Bio-Rad) and stained with a silver-staining kit (Invitrogen). Protein bands that specifically observed in the cell extracts transfected with pCAGGS Flag-C12orf48-HA were excised and analyzed by liquid chromatography-mass spectrometry (LC-MS/MS). The excised proteins were reduced in 10-mM tris(2-carboxyethyl)phosphine (Sigma-Aldrich) with 50-mM ammonium bicarbonate (Sigma-Aldrich) for 30 min at 37°C and alkylated in 50-mM iodoacetamide (Sigma-Aldrich) with 50-mM ammonium bicarbonate for 45 min in the dark at 25°C. Porcine trypsin (Promega, San Luis Obispo, CA) was added for a final enzyme to protein ratio of 1:20. The digestion was conducted at 37°C for 16 hr. The resulting peptide mixture was separated on a 100 μm × 150 mm HiQ-Sil C18W-3 column (KYA Technologies, Tokyo, Japan) using 30 min linear gradient from 5.4 to 29.2% acetonitrile in 0.1% trifluoroacetic acid (TFA) with total flow of 300 nL/min. The eluting peptides were automatically mixed with matrix solution (4 mg/mL α-cyano-4-hydroxy-cinnamic acid (Sigma-Aldrich), 0.08 mg/mL ammonium citrate in 70% acetonitrile, 0.1% TFA) and spotted

onto MALDI target plates (KYA Technologies). Mass spectrometric analysis was performed on 4800 Plus MALDI/TOF/TOF Analyzer (AB SCIEX Foster City, CA). MS/MS peak list was generated by the Protein Pilot version 2.0.1 software (AB SCIEX) and exported to a local MASCOT search engine version 2.2.03 (Matrix Science) for protein database search.

Flow Cytometry and Synchronization

KLM-1 cells were transfected with *C12orf48*-specific siRNA duplex (5′-CUAGUCAACUA CUGGAUUU-3′), *PARP-1*-specific siRNA duplex (5′-GAUAGAGCGUGAAGGCGAA-3′), and siEG FP duplex (5′-GAAGCAGCACGACUUCUUC-3′) as a negative control, respectively, by using Lipofectamine RNAiMAX (invitrogen) according to the manufacturer's recommendations. 96 hr after the transfection, the cells were fixed with 70% ethanol in PBS at 4°C, and incubated with 500 μL of PBS containing 0.5 mg of boiled RNase at 37°C for 30 min. Finally, 2×10^4 cells stained with 50 μg/mL propidium iodide were analyzed by means of Cell Lab Quanta^{TM} SC MPL Flow Cytometer (Beckman Coulter, USA). A complete block at G1/S-phase was achieved by treatment with 2 μg/mL aphidicolin for 24 hr. Then, cells were released from the cell-cycle arrest, harvested, and prepared for flow cytometry analysis (FACS).

In Vitro PARP-1 Auto-Poly(ADP-Ribosyl)ation Assays

In vitro PARP-1 automodification assays were performed as described previously (Di Palma et al., 2008). Briefly, 200 ng of the purified C12orf48 recombinant protein and 25 ng of the recombinant human PARP-1 (Alexis, San Diego, CA) were incubated in binding buffer (10 mM Tris-HCl, pH 7.5, 1 mM $MgCl_2$, 1 mM DTT) plus 10 μg/mL of sonicated DNA at 37°C for 10 min. The reactions were started by adding ^{32}P-labeled NAD^+, and incubated at 37°C for 10 min. After terminating the reactions with SDS sample buffer, the proteins were fractionated by 8% SDS-PAGE gel. Incorporation of ^{32}P-labeled NAD^+ to poly(ADP-ribosyl)ated proteins was visualized by autoradiography.

PARP-1 Activity in Cell Extracts

KLM-1 and SUIT-2 cells were transfected with *C12orf48*-siRNA, *PARP-1*-siRNA, or siEGFP (as a control), and collected 72 hr after the transfection. The knockdown effects were confirmed with anti-C12orf48 antibody and anti-PARP-1 antibody (Santa Cruz Biotechnology), respectively. PARP-1 activities in cell extracts were assayed using the universal colorimetric PARP assay kit (Trevigen, Gaithersburg, Maryland) based on the incorporation of biotinylated ADP-ribose onto histone H1 proteins. Briefly, cell extracts were loaded into a 96-well plate coated with histone H1, and incubated with biotinylated poly(ADP-ribose) and nicked DNA (Trevigen), size of which are 200–500 base pairs that are considered to be optimal for the PARP activation, for 1 hr. After wash with PBS containing 0.1% (v/v) Triton X-100, streptavidin-HRP (horseradish peroxidase) was added and incubated additionally for 20 min. TACS-Sapphire^{TM} was added subsequently to develop colors and the reaction was stopped by addition of 5% phosphoric acid. Finally, the absorbance was measured at 450 nm in a spectrometrophotometer. PARP-1 enzymatic activities were also evaluated by the use of mouse anti-poly(ADP-ribose) (PAR) monoclonal antibody (Trevigen). 25 μg of the cell extracts obtained from the KLM-1 cells that were transfected with *C12orf48*-siRNA, *PARP-1*-siRNA, or siEGFP (as a control), or 5 ng of recombinant human PARP-1 (Trevigen) were incubated for 20 min at 37°C in binding buffer (10 mM Tris-HCl, pH 7.5, 1 mM $MgCl_2$, 1 mM DTT) plus 10 μg/mL of sonicated DNA, and 200 μM NAD^+ (Sigma-Aldrich).

Sensitivity to DNA Damage

KLM-1 cells were transfected with oligo *C12orf48*-siRNA or siEGFP (as a control), and incubated for 48 hr to knockdown C12orf48 expression as described above. These transfected KLM-1 cells were trypsinized, and the number of living cells was counted. 5×10^5 cells were reseeded into the 6-well plates, and incubated with indicated concentrations of Adriamycin for 24 hr, H_2O_2 for 6 hr, or exposed to indicated intensity of UV radiation, and then incubated for 24 hr. Cell viability was measured using Cell-counting kit-8 as described above.

RESULTS

Overexpression of C12orf48 in PDAC Cells

Among the transactivated genes that were identified through our genome-wide microarray analysis of pancreatic cancer cells (Nakamura



Figure 1. Overexpression of C12orf48 in PDAC cells. (a) Semi-quantitative RT-PCR validated that C12orf48 expression was upregulated in the microdissected PDAC cells (Lanes 5–9), compared with microdissected normal pancreatic ductal cells (NP), whole normal pancreatic tissue (Panc), and vital organs (heart, lung, kidney, and liver). Expression of *ACTB* served as the quantitative control. (b) Left panel; multiple tissue Northern blot analysis showed the limited expression of *C12orf48* in the testis, among the human adult organs. Right panel; Northern blot analysis for *C12orf48* expression showed that several PDAC cell lines (KLM-1, PK-59, PK-45P, and SUIT-2) strongly expressed *C12orf48*, while other normal adult organs did not. (c) Immunocytochemical analysis with anti-C12orf48 polyclonal antibody showed that C12orf48 protein (green) was localized in the nuclei of KLM-1 cells. (d) Immunohistochemical study on PDAC tissues with anti-C12orf48 antibody. C12orf48 was strongly stained in the nuclei of PDAC cells (C1 × 200, C2 × 200, C3 × 200), while it was not stained in acinar cells and ductal epithelium cells of normal pancreatic tissues (N, ×200). In total, 21 of 31 (67.7%) PDAC tissues showed positive staining for C12orf48.

et al., 2004), we here focused on a novel gene *C12orf48* for this study. Semi-quantitative reverse transcription (RT)-PCR confirmed *C12orf48* overexpression in five of the nine pancreatic cancer cases examined (Fig. 1a). Northern blot analysis using the *C12orf48* cDNA fragment as a probe confirmed abundant expression of a 4-kb transcript in most of the eight PDAC cell lines we examined, but its expression was hardly detectable in any normal organs except the testis (Fig. 1b). The predicted C12orf48 protein does not contain any reported motifs or conserved domains in the database, but PSORTII program indicated C12orf48 likely to be a nuclear protein, which was confirmed by following immunocytochemical analysis using anti-C12orf48 polyclonal antibody we generated (Fig. 1c). Moreover, immunohistochemical analysis using anti-C12orf48 antibody showed positive signals in the nuclei of 21 of 31 PDAC tissues (Fig. 1d, panels C1–C3), whereas no staining was observed in any of normal pancreatic tissues (panel *n* in Fig. 1d).

Attenuation of PDAC Cell Viability by C12orf48 Knockdown

To investigate the biological significance of C12orf48 in PDAC cells, we constructed shRNA-expression vectors specific to *C12orf48* (si1, si2, si3) as well as that to siEGFP as a negative control, and transfected each of them into KLM-1 and SUIT-2 cells. Semi-quantitative RT-PCR showed significant knockdown effects on *C12orf48* expression in the cells transfected with si1 and si3, compared with the control (Fig. 2a). MTT assay and colony formation assay revealed that depletion of C12orf48 in KLM-1 and SUIT-2 cells (Figs. 2b and 2c) caused dramatic



Figure 2. Effect of C12orf48-shRNA on growth of PDAC cells. (a) Semi-quantitative RT-PCR examined the knockdown effect on *C12orf48* expression in PDAC cells (KLM-1 and SUIT-2 cells) transfected with shRNA-expressing vectors specific to *C12orf48* (si1, si2, si3) or control shRNA (siEGFP). (b) PDAC cells transfected with C12orf48 si1, or si3 shRNA vectors showed a drastic reduction in their viabilities. Each average is plotted with error bars indicating the standard deviation (SD) after 6-day incubation with Geneticin. *Y*-axis means absorbance at 490 nm, and at 630 nm as reference, measured with a microplate reader. These experiments were carried out in triplicate (*$P < 0.005$, Student's *t* test). (c) Colony formation assays in PDAC cells after *C12orf48* knockdown. Cells were stained with 0.1% crystal violet after 14-day incubation with geneticin. (d) FACS analysis was performed 96 hr after transfection with the indicated siRNA. The percentage of cells in subG1 phase was calculated. Treatment of KLM-1 with siRNA specific to *C12orf48* caused a drastic increase in sub-G1 population (40.96%).

reduction in the number of viable cells. Furthermore, we performed FACS analysis after depletion of C12orf48 by siRNA oligonucleotide in KLM-1 cells and found a drastic increase of cells at sub-G1 population (40.96%, Fig. 2d). We also observed similar effects of siRNA oligonucleotide for C12orf48 in SUIT-2 cells (data not shown). These findings indicated that C12orf48 could play critical roles in the growth of PDAC cells.

Interaction of C12orf48 with PARP-1

Since the biological functions of C12orf48 remain totally unknown, we attempted to isolate a protein(s) that could physically interact with C12orf48 protein. Protein complexes were immunoprecipitated by anti-Flag M_2 agarose from the lysates of the HEK293 cells in which Flag-tagged C12orf48 was exogenously introduced. The immunoprecipitated complexes were separated on SDS-PAGE and silver-stained. We found three bands (110, 90, and 63 kDa) in the immunoprecipitated complexes from the lysates of C12orf48-overexprerssing cells, but not in those from the mock cells (Fig. 3a). Among the three bands, the 63 kDa-band was considered to be Flag-tagged C12orf48 itself. We excised 110- and 90-kDa bands, and analyzed them by LC-MS/MS as described in Materials and Methods. As a result, the 110-kDa protein coimmunoprecipitated with C12orf48 protein was identified to be PARP-1 and the 90-kDa protein to be HSP90α (Fig. 3a). Immunoblotting by anti-PARP-1 antibody confirmed that PARP-1 was coimmunoprecipitated with Flag-tagged C12orf48 protein (Fig. 3b). Moreover, C12orf48 was also confirmed to be coimmunoprecipitated with PARP-1 protein (Fig. 3c).

Positive Regulation of PARP-1 Activity by C12orf48

To investigate the functional significance of the interaction between PARP-1 and C12orf48, PARP-1 automodification was investigated by incorporation of [^{32}P]NAD^+ in the absence or presence of purified



Figure 3. Identification of PARP-1 as an interacting protein of C12orf48. (a) Silver-staining of the immunoprecipitated complex separated on SDS-PAGE. Protein complexes were coimmunoprecipitated by anti-Flag M_2 agarose from the lysates of the HEK293 cells transfected with Flag-C12orf48 (right lane) or with mock (left lane). Two differential bands as well as Flag-C12orf48 (63 kD) were observed, and LC-MS/MS analysis identified PARP-1 (110 kD) and HSP90α (90 kD) as interacting proteins of C12orf48. (b) Western blot analysis using anti-PARP-1 antibody confirmed that PARP-1 protein was coimmunoprecipitated with Flag-C12orf48 protein. (c) Flag-C12orf48 expression vector was transfected to HEK293 cells without or with PARP-1-Myc expression vector. Cell lysates were immunoprecipitated by anti-Myc antibody. Flag-C12orf48 protein was coimmunoprecipitated with Myc-tagged PARP-1 protein.

recombinant C12orf48 protein in vitro. As shown in Figures 4a and 4b, we observed that addition of C12orf48 protein significantly enhanced the incorporation of $[^{32}P]NAD^+$ to recombinant PARP-1 protein in a dose-dependent manner when damaged DNA was coincubated, while this enhancement of PARP-1 automodification by C12orf48 was not observed in the absence of damaged DNA (data not shown). Furthermore, we transiently introduced C12orf48 into HEK293 cells and measured the PARP-1 activities in their lysates by the colorimetric PARP assay. In this experiment, PARP-1 in the cell extracts were activated by incubation with nicked DNA as described in Materials and Methods. As a result, we observed that PARP-1activities in the cell extracts were significantly enhanced by overexpression of C12orf48 (Fig. 4c).

Reduction of PARP-1 Activity by Depletion of C12orf48 in PDAC Cells

To examine the effect of C12orf48 on the PARP-1 activity in PDAC cells, we knocked down the expression of C12orf48 or PARP-1 itself in two PDAC cell lines, KLM-1 and SUIT-2, and measured the activities of PARP-1 in their cell lysates by the colorimetric PARP assay. The knockdown effects on C12orf48 and PARP-1 expression in KLM-1 and SUIT-2 cells were confirmed with anti-C12orf48 and anti-PARP-1 antibodies (Fig. 5a). Concordant with C12orf48 expression, the PARP-1 activities to modify histone H1 were decreased to 40.8 and 34.8% in C12orf48-depleted KLM-1 and SUIT-2 cells, respectively, compared with the control cells (Fig. 5b). The magnitude of this suppressive effect of C12orf48 on PARP-1 activity was almost same as the effect when PARP-1 itself was knocked down (Fig. 5b). Furthermore, we examined the level of poly(ADP-ribosyl)ation in the C12orf48-depleted cells by Western blot analysis using anti-poly (ADP-ribose) (PAR) antibody. As shown in Figure 5c, poly(ADP-ribosyl)ated proteins were detected at high molecular weights of more than 250 kD in the siEGFP-transfected control cells, while these poly(ADP-ribosyl)ation



Figure 4. Regulation of PARP-1 activity by C12orf48. (a) Effect of C12orf48 on the auto(ADP-ribosyl)ation of PARP-1 in vitro. PARP-1 was automodified by incorporation of [^{32}P]NAD^{+}. Lane1, purified recombinant C12orf48 protein alone; lane2, both recombinant C12orf48 and recombinant PARP-1 protein; lane3, recombinant PARP-1 alone. (b) In vitro PARP-1 auto(ADP-ribosyl)ation was enhanced by increasing amount of recombinant C12orf48 protein. (c) HEK293 cells were transfected with C12orf48-expressing vector and harvested at indicated time points. The expression of C12orf48 was quantified by the immunoblot (left panel). The activities of PARP-1 to modify histone H1 were measured using the colorimetric PARP assays (right panel). These experiments were performed three times (*$P < 0.05$, **$P < 0.0001$, Student's t test).

was drastically reduced in the cells treated with C12orf48-siRNA or PARP-1-siRNA. PARP-1 is known to be the primary target for PARP-1-mediated (ADP-ribosyl)ation in vivo, with greater than 90% of PAR found on PARP-1 (Ogata et al., 1981; Huletsky et al., 1989; D'Amours et al., 1999). Automodified PARP-1 is detected clearly as a high-molecular form due to poly (ADP-riobse) formation. Therefore, it seemed that most of PAR proteins detected here were originated from auto(ADP-ribosyl)ated PARP-1. It suggested that depletion of C12orf48 could decrease PARP-1 enzymatic activity both in vivo and in vitro. In addition, depletion of PARP-1 by siRNA in KLM-1 and SUIT-2 cells (Supplementary Fig. 1) induced significant reduction in the number of viable cells. Together, these findings presumably explain that C12orf48 depletion lead to the reduction of pancreatic cancer cell viability, in part, through its direct interaction with PARP-1. However, it cannot be excluded that other C12orf48-specific and PARP1-independent effects can also affect cancer cell viability, and further study is required to clarify the roles of C12orf48 in cancer.

Sensitization of PDAC Cells to DNA Damage by C12orf48 Depletion

PARP-1 activity is relevant for the ability of cells to repair damaged DNA. It has been reported that inhibition of PARP-1 activity could increase the susceptibility of cells to DNA damaging agents (Daniel et al., 2009; Horton et al., 2009). Given the findings that C12orf48 could regulate PARP-1 activity, we assessed that the C12orf48 depletion could sensitize cancer cells to various DNA damaging agents. As expected, C12orf48-depleted KLM-1 cells showed much higher sensitivities to Adriamycin treatment, UV irradiation, and H_2O_2 treatment (Fig. 6a). These findings suggested that C12orf48 might protect cancer cells from cell death following the DNA damage or cellular stresses in cancer cells through the regulation of poly(ADP-ribosyl)ation activity of PARP-1.

Effect of C12orf48 in Cell-Cycle Checkpoint

Cell-cycle checkpoints are considered to facilitate DNA repair before entering the next cell-



Figure 5. C12orf48-depletion reduced PARP-1 activity in PDAC cell extracts. (a) Western blot analysis using anti-C12orf48 and anti-PARP-1 antibodies confirmed knockdown effects of C12orf48 and PARP-1 expression in KLM-1 cells and SUIT-2 cells. (b) The activities of PARP-1 in the C12orf48-depleted or PARP-1-depleted cells were measured by the colorimetric PARP assays. *$P < 0.005$ by Student's t test. (c) PARP-1 enzymatic activities were investigated by anti-PAR antibody. Lane 1 and 2, recombinant PARP-1 protein; lane 3-6, KLM-1 cell extracts transfected with indicated siRNA. Automodified PARP-1 was detected at high molecular weights (>250 kD) only in the mixture with nicked DNA (Lane 2), but not the mixture without nicked DNA (Lane 1). Poly(ADP-ribosyl)ated proteins were observed at higher molecular weights (>250 kD) in the lysates of the siEGFP-transfected KLM-1 cells (Lanes 4 and 6). However, these poly(ADP-ribosyl)ation was diminished in the extracts of KLM-1 cells treated with PARP-1-siRNA (Lane 3) or C12orf48-siRNA (Lane 5).

cycle phases. Loss or attenuation of the checkpoint function may increase chances to cause gene mutations and chromosomal aberrations by affecting completion of the appropriate DNA repair. To test the effect of C12orf48 depletion on the cell-cycle progression, KLM-1 cells were synchronized at the G1-phase with aphidicolin treatment. After the release from the cell-cycle arrest, the cells depleted C12orf48 or PARP-1 entered into S-phase much faster than those treated with the control siEGFP (Fig. 6b). Six hours after the release from the arrest, approximately 73.3% of C12orf48-depleted cells and 75.7% of PARP1-depleted cells were already at S-phase. On the other hand, only 26.1% of the control cells (siEGFP) entered to S-phase. These findings indicated that depletion of C12orf48 or PARP-1 in PDAC cells could have some checkpoint dysfunction and resulted in very rapid progression from G1 to S-phase. We subsequently investigated the involvement of C12orf48 in the cell-cycle checkpoints after DNA damage by measuring the cell population at each cell-cycle phase after γ-irradiation. KLM-1 cells transfected with C12orf48-siRNA or siEGFP (as a control) were exposed to 3 Gy of γ-irradiation, and collected at various time-points after irradiation. Subsequent FACS analysis showed that C12orf48 depletion in KLM-1 cells enhanced G2/M arrest, compared with the control cells (Fig. 6c). Similarly, PARP-1 inhibitors were reported to enhance the G2 arrest after γ-irradiation (Nozaki et al., 1994). Taken together, our data implied that a decrease of PARP-1 activity in C12orf48-depleted cancer cells resulted in an enhancement of G2 arrest after γ-irradiation.

DISCUSSION

In this study, we focused on a novel gene *C12orf48*, one of the genes that were identified to be transactivated in PDAC cells through our genome-



Figure 6. C12orf48-depletion sensitized PDAC cells to DNA damage. (a) The survival was reduced in the C12orf48-depleted KLM-1 cells after the exposure to DNA damaging agents. Data are shown as the averaged value from three experiments. *X*-axis represents the concentration of Adriamycin (left) and H_2O_2 (right) or the intensity of UV for DNA damaging. *Y*-axis represents the relative ratio of the cell numbers that was calculated in absorbance of the diameter by comparison with the absorbance value of damage-negative cells as a control. $^*P < 0.05$, by Student's *t* test. (b) FACS analysis demonstrated S-phase progression of synchronized KLM-1 cells. Cells were synchronized at G1-phase by aphidicolin treatment and released into S-phase by culturing in aphidicolin-free media. The population of S-phase was calculated. (c) The effects of C12orf48 depletion on the population of G2/M phase after γ-irradiation in KLM-1 cells. The KLM-1 cells with or without C12orf48 depletion were irradiated at the dose of 3 Gy, and then collected at the indicated time points for flow cytometry analysis. *X*-axis represents the time points after γ-radiation; *Y*-axis shows the relative population changes of G2/M phase by comparison with the G2/M population value of the KLM-1 cells without irradiation.

wide expression profile analysis (Nakamura et al., 2004). Its overexpression was also observed in other therapy-resistant malignancies, such as cholangiocarcinoma (Jinawath et al., 2006), castration-resistant prostate cancer (Tamura et al., 2007), and relapsed small-cell lung cancer (Taniwaki et al., 2006), indicating that it might be featured at therapy-resistant or aggresive malignancies. On the other hand, its expression was hardly detectable in any normal adult organs except the testis, implicating C12orf48 to be a cancer-testis antigen. Depletion of C12orf48 in some of PDAC cells resulted in significant reduction of cancer cell viability and survival, implying its critical roles in pancreatic carcinogenesis.

Importantly, we demonstrated that C12orf48 protein could physically interact with PARP-1 and positively regulate the enzymatic activity of PARP-1, suggesting that C12orf48, termed PARP-1 binding protein (PARPBP), might be involved in multiple cellular processes including DNA repair, chromatin modification, cell-cycle progression and genomic stability through the interaction and regulation of PARP-1. PARP-1, as a DNA nick-sensor, binds to DNA single-strand breaks (SSBs) and double-strand breaks (DSBs), and has an emerging and indispensable role in their repair. In regard to DNA damage signaling, PARP-1 is promptly stimulated and recruits the enzymes required for DNA repair to the site of DNA damage. Hence, the activity of PARP-1 plays a key role in signaling and initiating these processes. We demonstrated that C12orf48-depletion sensitized some of PDAC cells to DNA damage, suggesting that C12orf48 is likely to participate in the process of DNA repair through the regulation of PARP-1. Recent studies indicated that PARP-1 could be stimulated through

its binding to nucleosomes, and modulate chromatin structures (Kim et al., 2004). Although the underlying mechanisms of PARP-1 in the modulation of chromatin structure are largely unknown, our results indicate that C12orf48 could possibly be involved in the chromatin modulation as well. Hence, development of drugs inhibiting the interaction between C12orf48/PARPBP and PARP-1 should be a good therapeutic approach to achieve very specific cytotoxicy to some of pancreatic cancer cells with minimum risk of adverse effects to normal organs.

C12orf48 has no known functional motif or conserved domain. However, a previous study on a mouse homologue of C12orf48 protein suggested its high binding affinity to single-stranded DNA and polyA homopolymers (Borsu et al., 2000). Cell-cycle checkpoints are essentially critical to ensure the fidelity of cell division in cells for verification of each of the cell-cycle processes that need to be accurately completed before going into the next phase. In our studies, we showed that knockdown of C12orf48 as well as PARP-1 caused the failure of the G1/S cell-cycle checkpoint which would usually prevent the replication of cells having defects in DNA. Hence, this G1/S checkpoint failure induced by depletion of C12orf48 or PARP-1 in cancer cells could increase a possibility of accumulation of genetic mutations and/or genomic instability, resulting in growth retardation of cancer cells. Moreover, knockdown of C12orf48 in cancer cells enhanced G2/M arrest in PDAC cells after γ-irradiation, consistent with previous reports describing that PARP-1 inhibitors enhanced the G2 arrest after γ-irradiation (Nozaki et al., 1994). However, since the underlying mechanism of PARP-1 enzymatic activity in G2-arrest regulation is unclear, additional studies will be required to clarify it.

REFERENCES

Audebert M, Salles B, Calsou P. 2004. Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J Biol Chem 279:55117–55126.

Audebert M, Salles B, Weinfeld M, Calsou P. 2006. Involvement of polynucleotide kinase in a poly(ADP-ribose) polymerase-1-dependent DNA double-strand breaks rejoining pathway. J Mol Biol 356:257–265.

Borsu L, Presse F, Nahon JL. 2000. The AROM gene, spliced mRNAs encoding new DNA/RNA-binding proteins are transcribed from the opposite strand of the melanin-concentrating hormone gene in mammals. J Biol Chem 275:40576–40587.

D'Amours D, Desnoyers S, D'Silva I, Poirier GG. 1999. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 342:249–268.

D'Silva I, Pelletier JD, Lagueux J, D'Amours D, Chaudhry MA, Weinfeld M, Lees-Miller SP, Poirier GG. 1999. Relative affinities of poly(ADP-ribose) polymerase and DNA-dependent protein kinase for DNA strand interruptions. Biochim Biophys Acta 1430:119–126.

Daniel RA, Rozanska AL, Thomas HD, Mulligan EA, Drew Y, Castelbuono DJ, Hostomsky Z, Plummer ER, Boddy AV, Tweddle DA, Curtin NJ, Clifford SC. 2009. Inhibition of poly-(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin Cancer Res 15:1241–1249.

Dantzer F, de La Rubia G, Menissier-De Murcia J, Hostomsky Z, de Murcia G, Schreiber V. 2000. Base excision repair is impaired in mammalian cells lacking poly(ADP-ribose) polymerase-1. Biochemistry 39:7559–7569.

de Murcia G, Ménissier de Murcia J. 1994. Poly(ADP-ribose) polymerase: A molecular nick-sensor. Trends Biochem Sci 19:172–176.

Di Palma T, de Cristofaro T, D'Ambrosio C, Del Prete D, Scaloni A, Zannini M. 2008. Poly(ADP-ribose) polymerase 1 binds to Pax8 and inhibits its transcriptional activity. J Mol Endocrinol 41:379–388.

DiMagno EP, Reber HA, Tempero MA. 1999. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology 117:1464–1484.

Durkacz BW, Omidiji O, Gray DA, Shall S. 1980. (ADP-ribose)n participates in DNA excision repair. Nature 283:593–596.

Hoeijmakers JH. 2001. Genome maintenance mechanisms for preventing cancer. Nature 411:366–374.

Horton TM, Jenkins G, Pati D, Zhang L, Dolan ME, Ribes-Zamora A, Bertuch AA, Blaney SM, Delaney SL, Hegde M, Berg SL. 2009. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: Influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther 8:2232–2242.

Hosokawa M, Takehara A, Matsuda K, Eguchi H, Ohigashi H, Ishikawa O, Shinomura Y, Imai K, Nakamura Y, Nakagawa H. 2007. Oncogenic role of KIAA0101 interacting with proliferating cell nuclear antigen in pancreatic cancer. Cancer Res 67:2568–2576.

Hosokawa M, Kashiwaya K, Eguchi H, Ohigashi H, Ishikawa O, Furihata M, Shinomura Y, Imai K, Nakamura Y, Nakagawa H. 2008. Over-expression of cysteine proteinase inhibitor cystatin 6 promotes pancreatic cancer growth. Cancer Sci 99:1626–1632.

Huletsky A, de Murcia G, Muller S, Hengartner M, Ménard L, Lamarre D, Poirier GG. 1989. The effect of poly(ADP-ribosyl)ation on native and H1-depleted chromatin. A role of poly(-ADP-ribosyl)ation on core nucleosome structure. J Biol Chem 264:8878–8886.

Iizumi M, Hosokawa M, Takehara A, Chung S, Nakamura T, Katagiri T, Eguchi H, Ohigashi H, Ishikawa O, Nakamura Y, Nakagawa H. 2006. EphA4 receptor, overexpressed in pancreatic ductal adenocarcinoma, promotes cancer cell growth. Cancer Sci 97:1211–1216.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. 2009. Cancer statistics, 2009. CA Cancer J Clin 59:225–249.

Jinawath N, Chamgramol Y, Furukawa Y, Obama K, Tsunoda T, Sripa B, Pairojkul C, Nakamura Y. 2006. Comparison of gene expression profiles between *Opisthorchis viverrini* and non-*Opisthorchis viverrini* associated human intrahepatic cholangiocarcinoma. Hepatology 44:1025–1038.

Jones P, Altamura S, Boueres J, Ferrigno F, Fonsi M, Giomini C, Lamartina S, Monteagudo E, Ontoria JM, Orsale MV, Palumbi MC, Pesci S, Roscilli G, Scarpelli R, Schultz-Fademrecht C, Toniatti C, Rowley M. 2009. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem 52:7170–7185.

Kameshita I, Matsuda Z, Taniguchi T, Shizuta Y. 1984. Poly (ADP-ribose) synthetase. Separation and identification of three proteolytic fragments as the substrate-binding domain, the DNA-binding domain, and the automodification domain. J Biol Chem 259:4770–4776.

Kashiwaya K, Hosokawa M, Eguchi H, Ohigashi H, Ishikawa O, Shinomura Y, Nakamura Y, Nakagawa H. 2009. Identification of C2orf18, termed ANT2BP (ANT2-binding protein), as one of the key molecules involved in pancreatic carcinogenesis. Cancer Sci 100:457–464.

Kim MY, Mauro S, Gévry N, Lis JT, Kraus WL. 2004. NAD^+-dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1. Cell 119:803–814.

Longley DB, Johnston PG. 2005. Molecular mechanisms of drug resistance. J Pathol 205:275–292.

Miknyoczki S, Chang H, Grobelny J, Pritchard S, Worrell C, McGann N, Ator M, Husten J, Deibold J, Hudkins R, Zulli A, Parchment R, Ruggeri B. 2007. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. Mol Cancer Ther 6:2290–2302.

Nakamura T, Furukawa Y, Nakagawa H, Tsunoda T, Ohigashi H, Murata K, Ishikawa O, Ohgaki K, Kashimura N, Miyamoto M, Hirano S, Kondo S, Katoh H, Nakamura Y, Katagiri T. 2004. Genome-wide cDNA microarray analysis of gene-expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection. Oncogene 23:2385–2400.

Nozaki T, Masutani M, Akagawa T, Sugimura T, Esumi H. 1994. Suppression of G1 arrest and enhancement of G2 arrest by inhibitors of poly(ADP-ribose) polymerase: Possible involvement of poly(ADP-ribosyl)ation in cell cycle arrest following gamma-irradiation. Jpn J Cancer Res 85:1094–1098.

O'Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G, Rocha C, Ossovskaya V, Sherman B, Bradley C. 2009. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. J Clin Oncol 27:3.

Ogata N, Ueda K, Kawaichi M, Hayaishi O. 1981. Poly(ADP-ribose) synthetase, a main acceptor of poly(ADP-ribose) in isolated nuclei. J Biol Chem 256:4135–4137.

Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, Curtin N, Boddy A, McHugh P, Newell D, Harris A, Johnson P, Steinfeldt H, Dewji R, Wang D, Robson L, Calvert H. 2008. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 14:7917–7923.

Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O'Connor MJ, Martin NM, Borst P, Jonkers J. 2008. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 105:17079–17084.

Takehara A, Eguchi H, Ohigashi H, Ishikawa O, Kasugai T, Hosokawa M, Katagiri T, Nakamura Y, Nakagawa H. 2006. Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4. Cancer Sci 97:1191–1197.

Takehara A, Hosokawa M, Eguchi H, Ohigashi H, Ishikawa O, Nakamura Y, Nakagawa H. 2007. Gamma-aminobutyric acid (GABA) stimulates pancreatic cancer growth through overexpressing GABAA receptor pi subunit. Cancer Res 67:9704–9712.

Tamura K, Furihata M, Tsunoda T, Ashida S, Takata R, Obara W, Yoshioka H, Daigo Y, Nasu Y, Kumon H, Konaka H, Namiki M, Tozawa K, Kohri K, Tanji N, Yokoyama M, Shimazui T, Akaza H, Mizutani Y, Miki T, Fujioka T, Shuin T, Nakamura Y, Nakagawa H. 2007. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene-expression profiles. Cancer Res 67:5117–5125.

Taniuchi K, Nakagawa H, Hosokawa M, Nakamura T, Eguchi H, Ohigashi H, Ishikawa O, Katagiri T, Nakamura Y. 2005a. Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating rho-family GTPases. Cancer Res 65:3092–3099.

Taniuchi K, Nakagawa H, Nakamura T, Eguchi H, Ohigashi H, Ishikawa O, Katagiri T, Nakamura Y. 2005b. Down-regulation of RAB6KIFL/KIF20A, a kinesin involved with membrane trafficking of discs large homologue 5, can attenuate growth of pancreatic cancer cell. Cancer Res 65:105–112.

Taniwaki M, Daigo Y, Ishikawa N, Takano A, Tsunoda T, Yasui W, Inai K, Kohno N, Nakamura Y. 2006. Gene expression profiles of small-cell lung cancers: Molecular signatures of lung cancer. Int J Oncol 29:567–575.

Wang M, Wu W, Wu W, Rosidi B, Zhang L, Wang H, Iliakis G. 2006. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res 34:6170–6182.

Wray CJ, Ahmad SA, Matthews JB, Lowy AM. 2005. Surgery for pancreatic cancer: Recent controversies and current practice. Gastroenterology 128:1626–1641.